Q2 2026 Holdings
Filed 2026-08-14 | 54 holdings | $4.2B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Abivax SA American Depositary Shares(ABVX) | COMM | 00370M103 | $800.6M | 6,007,834 | 19.2% |
| Tango Therapeutics Inc(TNGX) | COMM | 87583X109 | $283.9M | 9,081,201 | 6.8% |
| CG Oncology Inc(CGON) | COMM | 156944100 | $260.8M | 3,670,206 | 6.3% |
| Cogent Biosciences Inc(COGT) | COMM | 19240Q201 | $187.9M | 4,854,436 | 4.5% |
| Immunovant Inc(IMVT) | COMM | 45258J102 | $171.8M | 4,457,988 | 4.1% |
| Spyre Therapeutics Inc(SYRE) | COMM | 00773J202 | $168.7M | 1,900,582 | 4.1% |
| Dianthus Therapeutics Inc(DNTH) | COMM | 252828108 | $163.4M | 1,676,624 | 3.9% |
| Mirum Pharmaceuticals Inc(MIRM) | COMM | 604749101 | $124.3M | 1,062,049 | 3.0% |
| ZAI LAB LTD(ZLAB) | ADRS | 98887Q104 | $116.6M | 6,137,627 | 2.8% |
| Amylyx Pharmaceuticals Inc(AMLX) | COMM | 03237H101 | $112.1M | 6,243,812 | 2.7% |
| Monte Rosa Therapeutics Inc(GLUE) | COMM | 61225M102 | $111.9M | 4,622,151 | 2.7% |
| Biocryst Pharmaceuticals Inc(BCRX) | COMM | 09058V103 | $110.2M | 11,020,968 | 2.6% |
| VOR Biopharma Inc(VOR) | COMM | 929033207 | $104.4M | 5,673,078 | 2.5% |
| Tyra Biosciences Inc(TYRA) | COMM | 90240B106 | $103.8M | 3,248,980 | 2.5% |
| Dyne Therapeutics Inc(DYN) | COMM | 26818M108 | $102.5M | 4,615,144 | 2.5% |
| Disc Medicine Inc(IRON) | COMM | 254604101 | $98.1M | 1,341,862 | 2.4% |
| Relay Therapeutics Inc(RLAY) | COMM | 75943R102 | $80.0M | 4,273,356 | 1.9% |
| Savara Inc(SVRA) | COMM | 805111101 | $76.2M | 12,362,205 | 1.8% |
| Aura Biosciences Inc(AURA) | COMM | 05153U107 | $67.7M | 9,533,333 | 1.6% |
| Revolution Medicines Inc(RVMD) | COMM | 76155X100 | $63.8M | 340,899 | 1.5% |
| First Tracks Biotherapeutics(TRAX) | COMM | 337185102 | $58.3M | 2,895,304 | 1.4% |
| Kodiak Sciences Inc(KOD) | COMM | 50015M109 | $56.3M | 1,445,538 | 1.4% |
| Avalo Therapeutics Inc(AVTX) | COMM | 05338F306 | $55.8M | 3,017,120 | 1.3% |
| LB Pharmaceuticals Inc(LBRX) | COMM | 50180M108 | $47.0M | 1,447,310 | 1.1% |
| Century Therapeutics Inc(IPSC) | COMM | 15673T100 | $43.4M | 17,754,430 | 1.0% |
| Tectonic Therapeutic Inc(TECX) | COMM | 878972108 | $41.4M | 1,204,891 | 1.0% |
| Xencor Inc(XNCR) | COMM | 98401F105 | $39.5M | 2,452,138 | 0.9% |
| Surrozen Inc(SRZN) | COMM | 86889P208 | $38.2M | 1,473,101 | 0.9% |
| Editas Medicine Inc(EDIT) | COMM | 28106W103 | $36.0M | 11,111,111 | 0.9% |
| MBX Biosciences Inc(MBX) | COMM | 55287L101 | $35.9M | 650,000 | 0.9% |
| Pharvaris BV(PHVS) | COMM | N69605108 | $34.9M | 1,008,229 | 0.8% |
| Silence Therapeutics PLC(SLN) | ADRS | 82686Q101 | $33.3M | 3,033,560 | 0.8% |
| Inflarx N V(IFRX) | COMM | N44821101 | $32.5M | 14,500,000 | 0.8% |
| Altimmune Inc(ALT) | COMM | 02155H200 | $30.4M | 10,000,000 | 0.7% |
| Janux Therapeutics Inc(JANX) | COMM | 47103J105 | $27.5M | 1,789,617 | 0.7% |
| Perspective Therapeutics Inc(CATX) | COMM | 46489V302 | $27.0M | 7,915,567 | 0.6% |
| Agomab Therapeutics NV(AGMB) | ADRS | 00860C102 | $26.7M | 2,053,233 | 0.6% |
| Biohaven LTD(BHVN) | COMM | G1110E107 | $26.5M | 1,779,952 | 0.6% |
| Aktis Oncology Inc(AKTS) | COMM | 01021M104 | $22.5M | 696,560 | 0.5% |
| Alector Inc(ALEC) | COMM | 014442107 | $20.1M | 10,000,000 | 0.5% |
| Forte Biosciences Inc(FBRX) | COMM | 34962G208 | $19.6M | 920,000 | 0.5% |
| Monopar Therapeutics Inc(MNPR) | COMM | 61023L207 | $18.8M | 203,327 | 0.5% |
| Ocular Therapeutix Inc(OCUL) | COMM | 67576A100 | $16.2M | 1,647,752 | 0.4% |
| ADC Therapeutics SA(ADCT) | COMM | H0036K147 | $12.2M | 11,390,175 | 0.3% |
| ALX Oncology Holdings Inc(ALXO) | COMM | 00166B105 | $11.7M | 5,655,487 | 0.3% |
| Entrada Therapeutics Inc(TRDA) | COMM | 29384C108 | $7.8M | 1,060,230 | 0.2% |
| Cullinan Therapeutics Inc(CGEM) | COMM | 230031106 | $7.4M | 406,786 | 0.2% |
| Arvinas Holding Co LLC(ARVN) | COMM | 04335A105 | $5.9M | 707,098 | 0.1% |
| Korro BIO Inc(KRRO) | COMM | 500946108 | $5.5M | 416,301 | 0.1% |
| Research Alliance Corp CL A | COMM | G75226103 | $5.4M | 500,000 | 0.1% |